Content area
Abstract
Earlier this year, as a non-executive director of GlaxoSmithKline and as a member of the UK's Scientific Advisory Committee for Emergencies to advise the government over health issues related to the influenza A H1N1 pandemic, he faced calls to resign over a financial conflict of interest. Anderson was faced with the global economic crash, looming public spending cuts, and disappointing results in the research assessment exercise (RAE)-a recognised indicator of research quality, affecting student choice and the distribution of public funds for research.